Beyond lithium in the treatment of bipolar illness

Robert M. Post, Mark A Frye, Kirk D. Denicoff, Gabriele S. Leverich, Tim A. Kimbrell, Robert T. Dunn

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Dramatic changes have recently occurred in the availability of treatment options for bipolar illness. Second generation mood stabilizing anticonvulsants carbamazepine and valproate are now widely used as alternatives or adjuncts to lithium. High potency benzodiazepines are also used as alternatives to typical neuroleptics, and now atypical neuroleptics are demonstrating efficacy and better side-effects profiles than the typicals. Thyroid augmentation strategies and dihydropyridine L-type calcium channel blockers require further clinical trials to define their role. Putative third generation mood stabilizing anticonvulsants lamotrigine, gabapentin, and topiramate have unique mechanisms of action and deserve further systematic study, as does the potential role for nonconvulsive brain stimulation with repented transcranial magnetic stimulation (rTMS). These and a host of other potential treatment options now require a new generation of clinical trials to help identify clinical and biological markers of response and optimal use alone and in complex combination therapeutic regimens.

Original languageEnglish (US)
Pages (from-to)206-219
Number of pages14
JournalNeuropsychopharmacology
Volume19
Issue number3
DOIs
StatePublished - Sep 1998
Externally publishedYes

Fingerprint

Lithium
Anticonvulsants
Antipsychotic Agents
Biomarkers
Clinical Trials
L-Type Calcium Channels
Transcranial Magnetic Stimulation
Carbamazepine
Calcium Channel Blockers
Valproic Acid
Benzodiazepines
Thyroid Gland
Therapeutics
Brain

Keywords

  • Calcium channel blockers
  • Carbamazepine
  • Gabapentin
  • Lamotrigine
  • rTMS
  • Valproate

ASJC Scopus subject areas

  • Pharmacology

Cite this

Post, R. M., Frye, M. A., Denicoff, K. D., Leverich, G. S., Kimbrell, T. A., & Dunn, R. T. (1998). Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacology, 19(3), 206-219. https://doi.org/10.1016/S0893-133X(98)00020-7

Beyond lithium in the treatment of bipolar illness. / Post, Robert M.; Frye, Mark A; Denicoff, Kirk D.; Leverich, Gabriele S.; Kimbrell, Tim A.; Dunn, Robert T.

In: Neuropsychopharmacology, Vol. 19, No. 3, 09.1998, p. 206-219.

Research output: Contribution to journalArticle

Post, RM, Frye, MA, Denicoff, KD, Leverich, GS, Kimbrell, TA & Dunn, RT 1998, 'Beyond lithium in the treatment of bipolar illness', Neuropsychopharmacology, vol. 19, no. 3, pp. 206-219. https://doi.org/10.1016/S0893-133X(98)00020-7
Post RM, Frye MA, Denicoff KD, Leverich GS, Kimbrell TA, Dunn RT. Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacology. 1998 Sep;19(3):206-219. https://doi.org/10.1016/S0893-133X(98)00020-7
Post, Robert M. ; Frye, Mark A ; Denicoff, Kirk D. ; Leverich, Gabriele S. ; Kimbrell, Tim A. ; Dunn, Robert T. / Beyond lithium in the treatment of bipolar illness. In: Neuropsychopharmacology. 1998 ; Vol. 19, No. 3. pp. 206-219.
@article{104ddb4bb2bc49bf84fcf005f3f76e19,
title = "Beyond lithium in the treatment of bipolar illness",
abstract = "Dramatic changes have recently occurred in the availability of treatment options for bipolar illness. Second generation mood stabilizing anticonvulsants carbamazepine and valproate are now widely used as alternatives or adjuncts to lithium. High potency benzodiazepines are also used as alternatives to typical neuroleptics, and now atypical neuroleptics are demonstrating efficacy and better side-effects profiles than the typicals. Thyroid augmentation strategies and dihydropyridine L-type calcium channel blockers require further clinical trials to define their role. Putative third generation mood stabilizing anticonvulsants lamotrigine, gabapentin, and topiramate have unique mechanisms of action and deserve further systematic study, as does the potential role for nonconvulsive brain stimulation with repented transcranial magnetic stimulation (rTMS). These and a host of other potential treatment options now require a new generation of clinical trials to help identify clinical and biological markers of response and optimal use alone and in complex combination therapeutic regimens.",
keywords = "Calcium channel blockers, Carbamazepine, Gabapentin, Lamotrigine, rTMS, Valproate",
author = "Post, {Robert M.} and Frye, {Mark A} and Denicoff, {Kirk D.} and Leverich, {Gabriele S.} and Kimbrell, {Tim A.} and Dunn, {Robert T.}",
year = "1998",
month = "9",
doi = "10.1016/S0893-133X(98)00020-7",
language = "English (US)",
volume = "19",
pages = "206--219",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Beyond lithium in the treatment of bipolar illness

AU - Post, Robert M.

AU - Frye, Mark A

AU - Denicoff, Kirk D.

AU - Leverich, Gabriele S.

AU - Kimbrell, Tim A.

AU - Dunn, Robert T.

PY - 1998/9

Y1 - 1998/9

N2 - Dramatic changes have recently occurred in the availability of treatment options for bipolar illness. Second generation mood stabilizing anticonvulsants carbamazepine and valproate are now widely used as alternatives or adjuncts to lithium. High potency benzodiazepines are also used as alternatives to typical neuroleptics, and now atypical neuroleptics are demonstrating efficacy and better side-effects profiles than the typicals. Thyroid augmentation strategies and dihydropyridine L-type calcium channel blockers require further clinical trials to define their role. Putative third generation mood stabilizing anticonvulsants lamotrigine, gabapentin, and topiramate have unique mechanisms of action and deserve further systematic study, as does the potential role for nonconvulsive brain stimulation with repented transcranial magnetic stimulation (rTMS). These and a host of other potential treatment options now require a new generation of clinical trials to help identify clinical and biological markers of response and optimal use alone and in complex combination therapeutic regimens.

AB - Dramatic changes have recently occurred in the availability of treatment options for bipolar illness. Second generation mood stabilizing anticonvulsants carbamazepine and valproate are now widely used as alternatives or adjuncts to lithium. High potency benzodiazepines are also used as alternatives to typical neuroleptics, and now atypical neuroleptics are demonstrating efficacy and better side-effects profiles than the typicals. Thyroid augmentation strategies and dihydropyridine L-type calcium channel blockers require further clinical trials to define their role. Putative third generation mood stabilizing anticonvulsants lamotrigine, gabapentin, and topiramate have unique mechanisms of action and deserve further systematic study, as does the potential role for nonconvulsive brain stimulation with repented transcranial magnetic stimulation (rTMS). These and a host of other potential treatment options now require a new generation of clinical trials to help identify clinical and biological markers of response and optimal use alone and in complex combination therapeutic regimens.

KW - Calcium channel blockers

KW - Carbamazepine

KW - Gabapentin

KW - Lamotrigine

KW - rTMS

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=0032171374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032171374&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(98)00020-7

DO - 10.1016/S0893-133X(98)00020-7

M3 - Article

C2 - 9653709

AN - SCOPUS:0032171374

VL - 19

SP - 206

EP - 219

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 3

ER -